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Abstract
 Antibody responses have been used to characteriseBackground:
transmission and exposure history in malaria-endemic settings for over a
decade. Such studies have typically been conducted on well-standardised
enzyme-linked immunosorbent assays (ELISAs). However, recently
developed quantitative suspension array technologies (qSAT) are now
capable of high-throughput and multiplexed screening of up to hundreds of
analytes at a time. This study presents a customised protocol for the
Luminex MAGPIX  qSAT using a diverse set of malaria antigens. The aim
is to develop a standardised assay for routine serological surveillance that
is implementable across laboratories and epidemiological settings.
 A panel of eight  recombinant antigens,Methods: Plasmodium falciparum 
associated with long- and short-lived antibody responses, was designed for
the Luminex MAGPIX  platform. The assay was optimised for key steps in
the protocol: antigen-bead coupling concentration, buffer composition,
serum sample dilution, and bead storage conditions. Quality control
procedures and data normalisation methods were developed to address
high-throughput assay processing.  Antigen-specific limits of quantification
(LOQs) were also estimated using both in-house and WHO reference
serum as positive controls.
 Antigen-specific bead coupling was optimised across five serumResults:
dilutions and two positive controls, resulting in concentrations operational
within stable analytical ranges. Coupled beads were stable after storage at
room temperature (22⁰C) for up to eight weeks. High sensitivity and
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 room temperature (22⁰C) for up to eight weeks. High sensitivity and
specificity for distinguishing positive and negative controls at serum sample
dilutions of 1:500 (AUC 0.94 95%CI 0.91-0.96) and 1:1000 (AUC 0.96
95%CI 0.94-0.98) were observed. LOQs were also successfully estimated
for all analytes but varied by antigen and positive control.
 This study demonstrates that developing a standardisedConclusions:
malaria-specific qSAT protocol for a diverse set of antigens is achievable,
though further optimisations may be required. Quality control and data
standardisation methods may also be useful for future analysis of large
sero-epidemiological surveys.
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Introduction
Until recently, the vast majority of malaria antibody studies 
have sought to understand the acquisition of protective immu-
nity to inform vaccine development1,2. However, there is growing 
interest in identifying new serological markers of malaria expo-
sure for epidemiological surveillance3–5. Rational selection of 
these markers for population-wide sero-profiling could enable the 
development of improved tools for monitoring changes in malaria 
transmission. Such tools have the potential to simultaneously 
characterise both historical and recent patterns in malaria 
exposure.
Accurately quantifying antibody dynamics in these contexts 
requires population-representative or frequently-sampled lon-
gitudinal datasets3,6. Sero-epidemiological studies of this 
scale have historically used enzyme-linked immunosorbent assays 
(ELISAs), which are easily standardised, widely available, and 
ideal for high-throughput analysis of a single antigen (or the 
combined response to multiple antigens). However, the limited 
dynamic range and need for relatively high blood volumes 
make ELISAs less efficient for evaluating multiple analyte- 
specific responses. Conversely, protein microarrays allow 
high-throughput analysis of hundreds to thousands of analytes 
per sample7,8, but are still prohibitively expensive and not easily 
accessible by national malaria control programmes (NMCPs) or 
laboratories.
Cytometric bead array (CBA) and quantitative suspension array 
technologies (qSATs), such as Luminex xMAP© (Luminex 
Corp, Austin TX), are now available as affordable mid- to high-
throughput multiplexing platforms. These offer several advan-
tages, including the simultaneous quantification of 50-500 proteins 
in a single well, the use of standard 96- or 384-well plates, and 
requiring as little as 5μl of plasma or serum9–11. These platforms 
have also been shown to measure a larger dynamic range of 
antibody responses compared to ELISA12,13.
Optimisation of CBA and qSAT platforms can be complex for 
antigen panels designed to capture a wide range of antibody 
dynamics. A key challenge is achieving a high degree of mul-
tiplexing while retaining differential responses across a diverse 
set of antigens14. Additionally, standardised approaches for the 
epidemiological analysis of Luminex data are still in develop-
ment. A number of recent studies have assessed cluster-level 
antibody responses based on Luminex data for malaria15–18 and 
other infectious diseases19,20, but there is still a paucity of data 
on appropriate methods for standardisation and interpretation 
across laboratories, sites, and antigens.
In this study, we developed a customised panel of Plasmodium 
falciparum (Pf) recombinant antigens as serological markers 
of both historical and recent malaria exposure and optimised a 
protocol for the Luminex MAGPIX© qSAT platform. This includes 
five recently developed antigens previously validated in pro-
tein microarray studies for their association with recent malaria 
infection in Ugandan and Malian children3. For epidemiologi-
cal analysis, we present quality control procedures for high- 
throughput assay processing, data normalisation methods, and 
report estimates of antigen-specific limits of quantification (LOQs). 
The aim was to translate the development of a suite of mark-
ers for malaria exposure to a qSAT platform that is practical for 
epidemiological surveillance across laboratories and countries.
Methods
Assay conditions were assessed and optimised for key steps 
in the protocol: antigen-bead coupling concentration, buffer 
composition to reduce non-specific reactivity, serum sample 
dilution, and the impact of storage length and temperature on 
bead stability (Figure 1).
Antigen selection and design
A multiplex panel was developed for the Luminex MAGPIX© 
suspension bead array containing eight erythrocytic Pf recom-
binant proteins (Table 1). Antigens were selected from an initial 
screen of 856 candidates on an in vitro transcription and trans-
lation (IVTT) protein microarray assay based on their correla-
tion with previous malaria infection in children3. Each antigen 
was generated and expressed in Escherichia coli as glutathione 
S-transferase (GST)-tagged fusion proteins using methods 
as previously described by Herman et al.21, Tetteh et al.22, and 
Polley et al.23. The exception to the panel was PfAMA1, which 
was expressed in Pichia pastoris as a histidine-tagged protein24. 
Protein purification was conducted by affinity chromatogra-
phy (Glutathione Sepharose 4B (GE Healthcare Life Sciences) 
or HisPur Ni-NTA (Invitrogen) resins for GST and His 
tagged proteins, respectively), and the concentration, quality, and 
purity of the antigen yield was assessed using a Bradford assay 
and SDS-PAGE. Bacterial lysate was generated from the cul-
ture of untransformed E.coli and used in the preparation of assay 
buffers as non-specific protein to eliminate background 
reactivity to E.coli proteins3.
Positive and negative controls for assay optimisation
For the optimisation of the assay protocol, several different 
positive controls were used and are summarised for each test 
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Figure 1. Scheme describing the qSAT assay protocol. Assay conditions tested for optimisation indicated in green boxes and red text. 
Table 1. Summary of antigens in multiplex Luminex panel.
Gene ID Antigen 
name
Allele Expression Location Description
PF3D7_0930300 PfMSP119
† Wellcome GST Merozoite surface 19kDa fragment of MSP1 
molecule23
PF3D7_1133400 PfAMA1† FVO Hisx6 Sporozoite / 
Merozoite
Apical membrane 
antigen124
PF3D7_1035300 PfGLURP.R2 F32 N/A Merozoite Glutamate rich protein R225
PF3D7_0532100 Etramp5.Ag1 3D7 GST iRBC/PVM Early transcribed 
membrane protein 526
PF3D7_0423700 Etramp4.Ag2 3D7 GST iRBC/PVM Early transcribed 
membrane protein 427
PF3D7_0402400 GEXP18 3D7 GST Gametocytes Gametocyte exported 
protein 183
PF3D7_0501100.1 HSP40.Ag1 3D7 GST iRBC / 
Gametocytes
Heat shock protein 40, 
type II3
PF3D7_1002000 Hyp2 3D7 GST iRBC / PVM Plasmodium exported 
protein3
-- GST -- -- -- GST expression tag
-- TT -- -- -- Tetanus Toxoid
†Conformational protein. iRBC, infected red blood cell; PVM, parasitophorous vacuole membrane; GST, glutathione S 
–transferase.
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condition (Table 2). This included pooled serum from hyper-
immune individuals in Tanzania (CP3), Uganda (PRISM), 
The Gambia (Brefet) as well as the WHO reference serum 
(NIBSC 10/198)28. Individual plasma samples from European 
malaria-naive adults were used as negative controls.
Microsphere coupling, buffer, and sample dilution 
optimisation
Recombinant antigens were coupled to MagPlex© COOH-
microspheres or ‘beads’ (Luminex Corp., Austin TX) following 
the protocol described by the Luminex Corporation29. Optimal 
coating concentrations for each antigen were tested using a six-
point serial titration of protein. Starting dilutions were determined 
by the known immunogenicity range of each antigen (Table 3). 
Titrations were tested under a series of conditions to assess the 
variability across 1) two different positive pools (CP3 and WHO 
NIBSC 10/198) and 2) five serum sample dilutions (1:100, 
1:200, 1:400, 1:800, and 1:1600). All samples were incubated 
overnight in buffer B with E. coli lysate. The antigen titration 
at mid-point of the median fluorescence intensity (MFI) dose-
response curve (EC50 or MFI50) was calculated for each positive 
pool and serum dilution condition (15 in total for each antigen), 
using Equation 1 described further below. The median titration 
across all conditions was selected as the optimal coupling con-
centration for each antigen and used for large volume bead cou-
pling. Beads were then re-suspended in 1 mL of storage buffer 
(1x phosphate buffered saline (PBS pH 7.2), 0.05% Tween, 
0.5% bovine serum albumin (BSA), 0.02% sodium azide, 0.02% 
Pefabloc (Sigma)) and stored at 4°C until further use.
Antigen reactivity was tested for sensitivity to buffer 
composition and serum sample dilution. To reduce non-specific 
background reactivity for antigens expressed in E. coli, facto-
rial testing of the two buffer solutions (buffer A - 1xPBS, 0.05% 
Tween, 0.5% BSA, 0.02% sodium azide; and buffer B - 1xPBS, 
0.05% Tween, 0.5% BSA, 0.02% sodium azide, 0.1% casein, 
0.5% polyvinyl alcohol (PVA), 0.5% polyvinyl pyrrolidone 
(PVP)) was conducted. Both buffers were tested with or without 
supplementation of E. coli lysate (added at 15.25 μg/ml), result-
ing in a total of four different buffer compositions. Positive con-
trol samples were 40 individuals from Brefet, The Gambia and 
negative controls were 40 malaria-naïve European individu-
als (all samples tested at 1:100 dilution). The effects of buffers 
A and B - with or without E. coli - on MFI values of both 
positive and negative samples were assessed using linear regres-
sion with an interaction term to test for potentially synergistic 
effects on background reactivity by adding E. coli to buffer B.
A range of serum concentrations was also tested (1:100, 1:500, 
1:1000 and 1:2000) using samples from 20 individuals from 
endemic regions in Uganda, Tanzania, and The Gambia as 
positive controls and 20 malaria naïve European individuals 
as negative controls. All samples were incubated overnight in 
buffer B with E. coli lysate. Optimal serum sample dilutions 
were selected based on cross-validated Area Under the Receiver 
Operating Characteristics Curve (AUC) values, calculated 
from the sensitivity and specificity of continuous MFI values 
for predicting a positive or negative control using the ci.cvAUC 
function in the ‘cvAUC’ package version 1.1.0 (R version 3.5.1).
Table 2. List of assay conditions tested.
Optimisation Values tested Samples
Antigen concentration 6-dilution serial protein titration 
2 positive controls 
5 serum sample dilutions (1:100, 1:200, 1:400, 
1:800, 1:1600)
•   Tanzanian pooled serum (CP3) 
•   WHO reference serum (NIBSC 10/198)
Buffer composition Buffer A 
•   With E.coli lysate 
•   Without E.coli lysate 
Buffer B 
•   With E.coli lysate 
•   Without E.coli lysate
•   40 Gambian individuals (Brefet) 
•   40 malaria naive European blood donors (PHE) 
Samples tested at serum dilution of 1:100
Sample dilution 1:100, 1:500, 1:1000, 1:2000 •   Tanzanian pooled serum (CP3) 
•   2 sets of Ugandan pooled serum (Apac, PRISM) 
•   Gambian pooled serum (Brefet) 
•   12 Ugandan individuals 
•   4 Gambian individuals 
•   20 malaria naïve European blood donors (PHE) 
Samples incubated in buffer B with E.coli 
Microsphere storage
•   Length of time <4 weeks storage at 4°C 
6 months storage at 4°C
•   Tanzanian pooled serum (CP3) 
•   2 sets of Ugandan pooled serum (Apac, PRISM) 
•   Gambian pooled serum (Brefet) 
•   4 malaria naive European blood donors (PHE) 
Samples tested at serum dilution of 1:100 and 
incubated in buffer B with E.coli 
•   Temperature 1-8 weeks storage at: 
-20°C, 22°C, 37°C and 42°C
•   Tanzanian pooled serum (CP3) 
Samples tested at serum dilution of 1:100 and 
incubated in buffer B with E.coli 
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Table 3. Antigen coupling concentration titrations. Optimal range and final antigen concentration in 
bold.
Antigen titration (µg/mL)
Antigen 1 2 3 4 5 6 Final 
coupling 
concentration 
(µg/mL)
Final coupling 
concentration 
(ng/5000 beads)
PfMSP119 800.00 100.00 12.50 1.563 0.195 0.024 51.5 20.6
PfAMA1 600.00 75.00 9.375 1.172 0.147 0.018 3.85 1.54
PfGLURP.R2 300.00 37.50 4.688 0.586 0.073 0.009 0.042 0.017
Etramp5.Ag1 1000.00 125.00 15.625 1.953 0.244 0.031 243 97.2
GEXP18 750.00 93.75 11.719 1.465 0.183 0.023 618 247.2
HSP40.Ag1 800.00 100.00 12.50 1.563 0.195 0.024 91.5 36.6
Etramp4.Ag2 1000.00 125.00 15.625 1.953 0.244 0.031 32.5 13.0
Hyp2 350.00 43.75 5.469 0.688 0.085 0.011 197 78.8
Stability and reproducibility testing
To evaluate the impact of storage temperature, accelerated sta-
bility testing was conducted using aliquots of antigen-coupled 
beads stored for 1–8 weeks at -20°C, 22°C (room temperature), 
37°C and 42°C. Antigen-coupled beads were incrementally added 
to each storage temperature at intervals over an 8-week period, 
such that total storage time ranged from 1, 2, 4, and 8 weeks total. 
All the antigen-coupled beads were run simultaneously at the 
end of eight weeks with a single positive control titration, avoid-
ing the need to adjust for random effects due to week or posi-
tive control batch in subsequent regression analysis. Beads were 
assayed using a five-point serial dilution titration and the CP3 
Tanzanian positive pool (described above) at a 1:100 dilution in 
buffer B with E. coli lysate. The effect of each storage condi-
tion was assessed with multivariate linear regression to estimate 
change in MFI over time, adjusted for storage temperature and 
sample concentration and allowing for pairwise interaction 
between all covariates (storage temperature, storage time 
and sample concentration).
To assess the impact of long-term storage on stability and repro-
ducibility of results, two sets of antigen-coupled beads were 
assessed; one batch stored for 6 months at 4°C and another batch 
stored for less than 4 weeks at 4°C. Pooled serum of hyper- 
immune individuals from Tanzania, Uganda, and The Gambia 
were each tested in triplicate with beads from each storage con-
dition (less than 4 weeks and 6 months). Change in logMFI 
at 6 months compared to less than 4 weeks storage was 
assessed using linear regression, adjusting for antigen and 
allowing for random effects by sample and replicate.
Final qSAT assay procedure
General assay procedures were as follows and illustrated in 
Figure 1. First, an initial mixture containing 8 μl of each set of 
antigen-coupled microspheres and 5 ml of buffer A was pre-
pared, yielding approximately 1,000 beads per region per well 
(based on optimal conditions reported in previous studies5,13). 
Next, 50 μl of this combined microsphere mixture was added to 
a 96-well flat bottom plate (BioPlex Pro™, Bio-Rad Labora-
tories, UK) and washed once by placing the assay plate onto a 
magnetic plate separator (Bio-Plex®, Bio-Rad Laborato-
ries, UK) and pausing for 2 minutes. Plates were then inverted 
forcefully to remove the liquid and 100 μl of PBS-T (1xPBS, 
0.05% Tween-20) added to each well. Next, 50 μl of 
samples and controls were added to the plate and incubated 
in the dark at room temperature (RT) on a microplate shaker 
at 500 rpm for 90 minutes. Following three washes, 50 μl of flu-
orescent secondary antibody (Jackson Immuno 109-116-098: 
Goat anti-human Fcy-fragment specific IgG conjugated to 
R-Phycoerythrin (R-PE)), diluted to a 1:200 dilution with buffer 
A, was added to all wells and incubated for 90 minutes in the 
dark at RT at 500 rpm. After a further three washes, the plate was 
incubated in 50 μl of buffer A for 30 minutes. Plates received 
an additional wash and, after a final addition of 100 μl 1xPBS, 
were read using the Luminex MAGPIX© analyser. At least 
50 beads per analyte were acquired per sample and MFI data 
were used for analysis.
This protocol is used to screen samples from regions that may 
be co-endemic for both schistosomiasis and malaria, potentially 
causing non-malaria reactivity against GST-tagged fusion pro-
teins. Therefore, GST-coupled beads were included to quantify 
any GST-specific immunoglobulin (IgG) responses, which can 
be subtracted from total MFI against GST-tagged fusion proteins 
to better reflect malaria-specific IgG responses. Beads coupled 
with tetanus toxoid vaccine protein (TT) were also included as 
an internal assay quality control, given that measurable MFI val-
ues are expected for positive controls from regions where teta-
nus vaccine coverage is high. All data reported and analysed are 
in units of background subtracted MFI (Net MFI - blank wells).
Study samples used to develop standardisation methods
Samples used to validate data normalisation were based on 
all-age cross-sectional surveys conducted in July 2013 and 
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December 2013 in two villages in the West Coast Region and 
two villages in the Upper River Region (N=1,813) of The 
Gambia30. Samples were eluted from a 6-mm dried blood spot 
(DBS) punch, corresponding to 4 μl of whole blood, and shaken 
overnight at room temperature in 200 μl of elution buffer contain-
ing 1xPBS, 0.05% sodium azide and 0.05% Tween-20, yielding an 
initial 1:50 sample dilution. At least 1 day prior to assay process-
ing, samples were further diluted to a final 1:500 dilution using 
10 μl of the 1:50 pre-dilution sample and 90 μl of blocking 
buffer B with E.coli extract to prevent non-specific binding. 
Negative and positive controls were also incubated one day prior 
in buffer B with E. coli, with negative controls prepared at a 
1:500 dilution and Gambian pooled positive controls in a 6-point 
5-fold serial dilution (1:10 – 1:31,250). Two wells on each 
plate containing only antigen-coupled beads and buffer B, but 
absent of any human serum, were included to measure back-
ground signal. A pool of 22 serum samples from malaria hyper- 
immune individuals in Upper River Region, The Gambia were 
used as a positive control, and plasma from 10 European malaria- 
naive adults were used as negative controls.
Estimating antigen-specific limits of quantification
To estimate the lower limit of quantification (LLOQ) and 
higher limit of quantification (HLOQ) for each antigen, two 
positive controls were tested (WHO NIBSC 10/198 and 
Tanzanian pooled positives (CP3)) using a 16-point 3-fold serial 
dilution, starting at 1:2. For each antigen and positive con-
trol, standard curves were fitted with Equation 1. The LLOQ 
MFI was defined as the MFI value where the upper 95%CI 
of the MFI
min parameter estimate is equivalent to the lower 
95%CI of the standard curve estimate, and the HLOQ MFI 
where the lower 95%CI of the MFI
max 
parameter estimate is 
equivalent to the upper 95%CI of the standard curve estimate31.
Quality control
For quality control of samples from The Gambia, Levey- 
Jennings charts15 were used to plot the mean MFI values of three 
concentrations from the positive control standard curve (high, 
1:10; medium, 1:50; and low, 1:250) as well as the background 
values for each plate. The acceptable range of MFI values for 
inclusion in data analysis was defined as the mean ± two stand-
ard deviations of a subset of ten reference plates (selected based 
on the quality and consistency of their standard curve values). 
Plates with MFI values outside this range for at least two stand-
ard curve dilutions and at least three antigens were rejected and 
repeated. Assays were processed in-country using beads trans-
ported from London. To assess the potential impact of interruption 
to the cold chain on bead stability, points on the Levey-Jennings 
plots were also ordered by date of plate processing and linear 
regression used to test for potential changes over time.
Immunoassay data normalisation
To account for observed between plate variation in posi-
tive control standard curves, data were adjusted using a loess 
normalisation method32. This method was tested using cross-
sectional samples from The Gambia, as described above. First, 
positive control standard curves for each plate of antibody 
concentrations versus MFIs were fitted using a 4-parameter 
logistic equation31,33,34:
               
50
– )
 
1 ( )[ ]
+
+
min max
max
MFI MFI
MFI MFI dilution slope
MFI
(
=
        (Equation 1)
where MFI
max
 is the upper asymptote or maximum MFI 
response of the standard curve, MFI
min is the lower asymptote or 
minimum MFI response of the standard curve, MFI50 is 50% 
of MFI
max
, dilution is positive control serum sample serial dilu-
tion, and slope is the Hill coefficient or slope factor of the dose- 
response curve. EC50 is the concentration or dilution that 
corresponds to MFI50.
Next, ten reference plates from the study were selected based 
on the quality and consistency of their standard curve fits. For 
each antigen, a composite standard curve was computed by 
calculating the mean MFI values for the reference plates for 
100 dilutions between the highest and lowest dilution on the 
standard curve. For each plate, the plate-to-reference standard 
curve MFI difference (∆MFI) was calculated for these 
100 concentration points and a loess regression fit to ∆MFI 
as a function of mean MFI. The raw MFI data for all samples 
on the plate were then adjusted by the predicted ∆MFI based on 
the loess regression fit. Data were not corrected for background 
signal given that the between plate variation was already 
accounted for in the loess normalisation and all background 
MFIs were below 30 and therefore negligible.
Ethical approval
Written informed consent was obtained for all study partici-
pants. Ethical approval for the use of the Tanzanian samples was 
obtained from the institutional review boards of the National 
Institute of Medical Research of Tanzania, Kilimanjaro Christian 
Medical Centre (KCMC), and the London School of Hygiene 
& Tropical Medicine (LSHTM). For the Uganda (PRISM) 
samples, ethical approval was obtained from the Makerere 
University School of Medicine Research and Ethics Commit-
tee (REC REF 2011-203), Uganda National Council for Science 
and Technology (HS 1074), LSHTM Ethics Review Com-
mittee (Reference 6012) and the University of California, 
San Francisco on Human Research (Reference 027911). Finally, 
for the collection of the Gambian samples ethical approval was 
granted by the Scientific Coordinating Committee of the Medi-
cal Research Council (MRC) Laboratories in The Gambia and 
by the Joint MRC/Gambian Government Ethical Committee.
Results
Antigen to microsphere coupling
Optimal protein concentration for microsphere coupling, as 
determined by the titration with the MFI value closest to EC50 
of the dose-response curve, varied by antigen and ranged from 
as low as 0.017 ng/5000 beads for PfGLURP.R2 to 618 ng/5000 
beads for GEXP18 (Figure 2, Table 3), depending on the immu-
nogenicity of the recombinant protein. While some variation in 
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Figure 2. Titration of antigen concentration for microsphere coupling using two positive controls at 1:400 serum dilution. Antigens 
with maximum MFI values between 20,000 and 50,000 (PfMSP119, PfAMA1 and PfGLURP.R2) shown in (A) and (B) and between 1,000 and 
20,000 (Etramp5.Ag1, GEXP18, HSP40.Ag1, Etramp4.Ag2, Hyp2) in (C) and (D). Coupled microspheres were tested on two positive controls: 
CP3 (left) and WHO reference 10/198 (right). Optimal antigen coupling concentration (median EC50 across all sample dilutions and positive 
controls) are indicated as solid filled circles. *For PfGLURP.R2, the two highest antigen concentrations (shown as triangles) were not used to 
fit standard curves to exclude the influence of prozone effect.
estimated EC50 values for each antigen was observed between 
sample dilutions and positive controls (Supplementary Table 
S1), selecting the median EC50 across all conditions as the opti-
mal antigen-coupling concentration translated to MFI values on 
the linear portion of the dose-response curve, resulting in anti-
body responses measurable within a stable analytical range 
(Figure S1–Figure S3). A sigmoidal curve could be fit to 
the data for all antigens except Hyp2, where the midpoint between 
the two lowest titrations was selected as the optimal antigen 
concentration instead of the EC50 (Table 3, Supplementary 
Table S1).
Bead storage stability
The effect of storage temperature on MFI signal over time varied 
by antigen, based on multivariate linear regression of change 
in MFI by storage week adjusted for temperature and serum 
sample dilution (Figure 3, Supplementary Table S2 and Sup-
plementary Table S3). Compared to storage at –20°C, all tested 
temperatures (22°C, 37°C, and 42°C) were associated with a 
decrease of over 1,000 MFI per week of storage for GEXP18, 
HSP40.Ag1, Etramp4.Ag2 and Hyp2. For Etramp5.Ag1, 
PfMSP119 and PfGLURP.R2, degradation of more than 
1,000 MFI per week was only observed at storage tempera-
tures of 37°C and 42°C. No significant decreases in MFI signal 
were observed for PfAMA1 at any storage temperature. There 
was no significant degradation in signal between samples 
tested with beads stored for 6 months at 4°C compared to less 
than 4 weeks at 4°C, based on linear regression of logMFI 
with respect to time, after adjusting for antigen and allowing 
for random effects for sample and replicate.
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Figure  3. Bead stability by  temperature,  storage  time and dilution  factor. Difference in the median fluorescence intensity (∆MFI), of 
antigen-coupled beads stored at 22°C, 37°C and 42°C (compared to reference storage temperature of -20°C) after 1, 2, 4 and 8 weeks, 
and tested at six different positive control sample dilutions. Boxplots are based on data across all serum sample dilutions with median and 
interquartile range shown at each time point.
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Figure 4. Median fluorescence intensity (MFI) for PfAMA1 and GEXP19 of positive and negative samples for each buffer composition. 
Buffer compositions tested include buffer A (red), buffer A with E. coli lysate (pink), buffer B (blue), and buffer B with E. coli lysate (light blue). 
MFI for positive samples shown in colour (left) and corresponding negatives samples in grey (right) for each buffer composition.
Buffer composition
In the absence of clarified E. coli lysate as a blocking agent 
against non-specific antibody binding to bacterial proteins, no 
significant differences in mean MFI were observed between 
the buffer compositions for both PfAMA1 and GEXP18 
(Figure 4, Supplementary Table S4). The addition of the bac-
terial lysate was not associated with significant differences in 
MFI for yeast-produced PfAMA1. However, for GEXP18, 
the addition of the bacterial lysate resulted in a significant 
reduction in non-specific binding for both malaria endemic 
(-3,203.50 MFI, p=0.035) and malaria naïve samples (-5,857.30 
MFI, p<0.001). The combination of buffer B and E. coli lysate 
did not have a synergistic reduction on background reactivity.
Serum sample dilution
Across all antigens tested, compared to serum dilution of 
1:100, reductions in MFI values for negative controls were 
observed for sample serum dilutions of 1:500 (-911 MFI, 
p<0.001) and 1:1000 (-1,053, p < 0.001). These same serum 
dilutions maintained higher positive control values compared to 
a serum dilution of 1:2000 (Supplementary Figure S7). After 
adjusting for antigen, positive controls had an increased 
signal of 5,986 MFI (p<0.001) at a serum dilution at 1:500 and 
3,006 MFI (p<0.001) at a serum dilution of 1:1000 compared 
to the average MFI signal at 1:2000. Higher sensitivity and 
specificity values were observed for serum dilutions 1:500 
(AUC 0.94 95%CI 0.91-0.96) and 1:1000 (AUC 0.96 95%CI 
0.94-0.98) compared to serum dilutions 1:100 (AUC 0.89 95%CI 
0.86-0.93) and 1:2000 (AUC 0.91 95%CI 0.89-0.95), based 
on continuous MFI values across all antigens.
Limits of quantification
The limits of quantification of the assay differed by antigen and 
positive control used (Figure 5, Table 4). The highest HLOQs 
estimated were for PfAMA1, PfGLURP.R2, Etramp5.Ag1 
and Etramp4.Ag2 (greater than 40,000 MFI using the CP3 
Tanzanian positive control and greater than 30,000 MFI using 
the WHO reference standard). Estimated HLOQs for PfMSP119, 
GEXP18, and HSP40.Ag1 ranged between 20,859 and 
32,135 MFI across both positive controls, while the low-
est estimated HLOQ was for Hyp2 (below 20,000 MFI for both 
controls). The lowest estimated LLOQs were for PfMSP119, 
GEXP18, Hyp2, HSP40.Ag1 (below 500 MFI using the 
CP3 positive control), while estimated LLOQs for PfAMA1, 
PfGLURP.R2, Etramp5.Ag1, and Etramp4.Ag2 ranged 
926–3,439 MFI across both positive controls tested.
Based on the CP3 positive control, the dynamic range was larger 
compared to the WHO reference control (e.g., both a lower 
LLOQ and higher HLOQ) for nearly all antigens including 
PfMSP119, PfAMA1, Etramp5.Ag1, Etramp4.Ag2, GEXP18, 
and Hyp2. PfGLURP.R2 showed a higher HLOQ based on 
Tanzanian positive controls compared to the WHO reference 
standard, but also had a higher LLOQ. On the other hand, 
HSP40.Ag1 showed a lower LLOQ based on CP3 compared 
to the WHO reference, but also had a lower HLOQ.
Quality control
A total of 7,868 blood samples from The Gambia cross- 
sectional study were processed (96×96-well plates). Out of 
96 plates, 3 fell outside the acceptable range of MFI values and 
were repeated. Degradation of MFI signal after exposure of 
antigen coupled beads to storage conditions above room temper-
ature was also observed over a period of two months of sample 
processing, based on linear regression of MFI by date of plate 
processing (Supplementary Figure S8). For positive controls 
run at a dilution of 1:250, mean MFI for PfAMA1 at the start 
of sample processing was 24,480 and decreased at a rate of 
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Figure 5. Limits of quantification. Median fluorescence intensity (MFI) values are shown for pooled Tanzanian hyper-immune serum CP3 
(blue) and WHO reference serum (red) in a 12-point serial dilution. Horizontal lines represent the mean and 95% confidence intervals of the 
upper and lower asymptotes of the sigmoidal curve for CP3 (blue), WHO (red), and the mean background MFI in green.
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Table 4. Limits of quantification at 1:400 serum 
sample dilution. Units in median fluorescence 
intensity.
CP3 WHO
LLOQ HLOQ LLOQ HLOQ
PfMSP119 66 22,093 399 20,859
PfAMA1 3,256 49,612 3,439 39,205
PfGLURP.R2 2,533 40,691 1,754 35,913
Etramp5.Ag1 1,480 43,994 2,944 39,794
GEXP18 258 26,962 1,151 25,048
HSP40.Ag1 418 26,273 822 32,135
Etramp4.Ag2 926 52,967 1,912 38,082
Hyp2 132 15,570 379 10,042
61 MFI per plate (p=0.0104) over the course of two months. For 
GEXP18, mean MFI was 8,209 at the start of sample process-
ing and declined at a rate of 31 MFI per plate (p=0.007) over the 
same period.
Data normalisation
Proportional differences in plate-specific MFI values com-
pared with mean MFI values of reference plates (indicated as 
∆MFI in Figure 6) were highly dependent on the MFI range 
(Figure 6, Supplementary Figures S9-11). In other words, MFIs 
in the higher end of responses could show larger between-plate 
variations than MFIs in the lower end of responses (or 
vice versa) and may not be easily adjusted for using one pro-
portional factor across the full range of MFI values- the method 
typically used for normalising ELISA-based data. The extent 
of the variations differed by plate and antigen. Therefore, 
the loess normalisation allowed for raw data to be adjusted 
Figure  6.  Loess  normalisation  for PfAMA1  and GEXP18. Loess normalisation of antigens PfAMA1 and GEXP18 is illustrated for one 
example plate based on cross-sectional samples from The Gambia. Panels A and B show the loess fit (red) and linear fit (blue) of ∆ MFI on 
the y-axis (the difference in unadjusted MFI of the standard curve of a single plate and the mean MFI of all standard curves from ten reference 
plates) and mean MFI on the x-axis. Panels C and D show the raw MFI values of individual samples on the x-axis versus normalised MFI values 
on the y-axis, and the equality line is shown diagonally in red. 
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and weighted according to MFI range-specific differences 
(Figure 6, Supplementary Figures S9-11). Additionally, loess 
regression provided a better fit to the ∆MFI versus mean MFI 
data compared to linear regression, indicating that it may 
provide better adjustment values for plate-specific normalisation.
Discussion
This study builds on previous work optimising the Luminex® 
qSAT as a multiplex platform of Plasmodium antigens. To develop 
a panel of serological markers for the characterisation of both 
historical and recent malaria exposure, the methods tested here 
aimed to standardise a protocol that could consistently meas-
ure a large range of antibody responses. This included the 
optimisation of antigen-to-bead coupling concentrations, test-
ing of coupled-bead stability at a range of temperatures reflec-
tive of variable storage conditions across laboratories, as well as 
buffer composition and serum sample dilution to minimise 
non-malaria specific background reactivity.
Results showed that storage of antigen-coupled beads at tem-
peratures below 37°C, and ideally at room temperature or 
lower, minimised degradation of MFI signal over an 8-week 
period for all antigens. Some antigens, such as PfAMA1, exhib-
ited more stability than others, where no significant degradation 
in MFI signal was observed over an eight-week period even 
at temperatures up to 42°C. Storage at room temperature also 
affected the bead stability for GEXP18, HSP40.Ag1, Etramp4.
Ag2 and Hyp2. This is consistent with previous studies 
reporting that stability of beads is antigen-specific. This sug-
gests that additional formulations to improve bead stability, 
such as lyophilisation in the presence of stabilisers, could 
be explored to minimise the impact on assay results. This is 
particularly critical when reagents are subject to transport or stor-
age conditions with a high risk of interruption to the transport 
cold chain. Temperatures of 22°C and above were tested in this 
study to assess the potential impact of disrupted cold chain 
during shipping to or long-term storage in laboratories in low- and 
middle-income settings. Further work should also investigate bead 
stability during long-term storage at 4°C, the standard storage 
condition for most research groups using Luminex platforms. 
Optimal antigen-to-bead coupling concentrations were deter-
mined for eight Pf antigens, including five markers of recent 
malaria exposure3. These concentrations were selected to 
cover a range a positive controls and serum sample dilutions 
allowing for generalisability across multiple study conditions. 
Previous studies have found that bead coupling concentra-
tion is the most consistent factor influencing assay variability. 
Failing to control the density of antigens on the microsphere sur-
face may result in either sub-optimal coating and low reactivity 
or over-coating and subsequent precipitation or aggregation of 
beads on the bottom of the plate, impairing surface suspension 
antibody binding13. The degree to which this occurs and the 
tendency for non-uniform protein aggregation may also be 
antigen-specific, depending on the physical characteristics 
of protein structure. New coupling methods are currently in 
development, including biotinylated microspheres that allow 
coupling to specific antigen regions for more consistent 
protein orientation. Future work should validate the analytical 
reproducibility of these coupling concentrations by moni-
toring the consistency in MFI signal between bead sets and 
recombinant protein batches. This may also identify antigens 
that may be better suited on either bead-based or microarray 
platforms. Given that protocols are being developed for high- 
throughput processing, the selection of optimal bead coupling 
concentrations should ideally ensure a consistent analytical sig-
nal across bead sets (i.e., close to the EC50 point on the standard 
curve), while minimising the amount of antigen needed to 
achieve cost and volume efficiencies over time. If these analytical 
and operational challenges can be met across a diverse set 
of antigens, there may be strong potential for including these 
analytes on larger multi-disease Luminex panels.
The inclusion of E. coli lysate in the sample incubation buffer 
was found to be an effective blocking agent, particularly 
against non-specific antibody binding to antigens expressed in 
E. coli by significantly reducing the MFI signal in negative sam-
ples. The impact of the addition of the E. coli lysate is suggestive 
of co-purification of E. coli proteins, for which there was 
little evidence by ELISA but are likely only detected on the 
Luminex platform due to the higher dynamic range. Moving for-
ward, the inclusion of additional chromatography separation 
techniques would minimise the presence of any co-purifying 
proteins and potentially negate the need for the E. coli lysate 
additive. Serum sample concentration was also optimal at both 
1:500 and 1:1000 to reduce non-specific background reactiv-
ity in negative samples while retaining a measurable degree of 
reactivity in positive samples. These serum dilutions had higher 
sensitivity and specificity for identifying positive control sera 
compared to dilutions of 1:100 and 1:2000. Several other assay 
conditions have been validated in previous studies. This includes 
the testing of 1,000 compared to 2,000 beads per well5,13, 
processing samples in duplicate5,14, the use of plasma compared 
to DBS35, and the comparison of single-plex with multiplex 
platforms5,35. Based on these studies, the protocol presented 
here uses 1,000 beads as an optimal baseline condition. 
Additionally, processing samples in duplicate, the use of plasma, 
and single-plex platforms did not significantly improve assay 
results. Therefore, optimal conditions confirmed from previous 
studies were incorporated into this protocol but not investigated 
further.
This study also reports antigen-specific limits of quantification 
(LLOQs and HLOQs) for several new Pf recombinant proteins, 
where the dynamic range varied between antigens and posi-
tive controls used. The WHO reference standard was found to 
have a narrower dynamic range compared to in-house positive 
control sera, which has also been observed in previous studies 
using the WHO positive control36. This is likely due to the selec-
tion of sera for this reference standard based on small number 
of antigens primarily associated with long-lived antibody 
responses (PfMSP119, PfAMA1, and PfCSP) and from only one 
geographical location (Kenya). Therefore, it may not be well 
suited for capturing short-lived antibody responses in populations 
from other endemic settings. Future work should consider how 
reference standards can be further improved to maximise the 
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measurable range for a larger selection of Pf antigens and across 
different geographical regions and also determine the LOQs 
across a range of sample serum dilutions currently being used.
Several challenges remain for the further development of mul-
tiplex serological platforms for malaria surveillance. First, 
many Luminex-based malaria studies currently use antibody 
concentrations estimated from the positive control standard curve 
for epidemiological analysis. As already reported in previous 
studies, assay conditions can affect the fit of the standard curve 
used to normalise the data to arbitrary concentration units. This 
potentially results in large deviations in concentration estimates. 
MFI responses measured independently from a standard curve 
might reflect true variation, while normalisation methods that 
convert to relative concentration values will be more influenced 
by the precision of the statistical fit of the standard curve36,37. 
Therefore, we use a loess normalisation method for standard-
ising data between assays, which attempts to maintain units 
in MFI values while also accounting for dilution-dependent 
variability in signal (i.e., magnitude of between plate variation 
that differs by MFI range). The robustness of this procedure, 
however, should be validated with additional laboratory data. 
For example, repeat testing of one set of endemic sera across 
multiple plates to simulate assay variability can be used to esti-
mate residual between-plate variance after data normalisation 
and to determine if the variance is antigen specific. An assess-
ment of potential overfitting using loess compared to linear 
regression or other normalisation methods should also be 
explored. It is also important to note that because normalisation is 
dependent on the standard curve, and adjustment of data 
below or above the minimum and maximum MFI values of the 
positive control titrations should be avoided as it may be dif-
ficult to extrapolate the relationship at these extremes (as seen 
with PfMSP119, Supplementary Figure S9). Therefore, designing 
standard curves to include titrations matching the range of MFI 
values expected in the samples being processed is important 
when using this normalisation method. 
The ultimate utility of these assays will be the application to 
high-throughput processing in endemic country laboratories. 
Minimal specialist equipment is required aside from a Luminex 
reader, a magnetic plate, and coupled microspheres and 
standard ELISA laboratory reagents. Therefore, Luminex-based 
processing is feasible in a range of endemics settings, from 
local hospitals with back-up electric generators (with consist-
ent supply for at least two 90 minutes incubations and a one 
hour plate reading) to larger laboratories in urban settings. This 
will likely require further validation of bead stability during 
field-based transport and storage conditions. To confirm the repro-
ducibility of the assay and data standardisation methods, between 
laboratory and user variability testing should be explored. The 
application of these data to epidemiological analysis will also 
need to consider antigen-specific kinetics across different 
endemic settings, in order to validate the use of novel serological 
markers of recent malaria exposure for routine surveillance or 
the evaluation of community-based efficacy trials. Standardised 
methods for determining sero-positivity thresholds for new 
antigens not previously used should be established.
Data availability
Underlying data
Raw data for this study, including output data for antigen and 
serum sensitivity and stability testing, output data from qSAT 
assays and data for validation and standardisation, are available 
on OSF. DOI: https://doi.org/10.17605/OSF.IO/AUJ3532.
Extended data
Extended data are available on OSF. DOI: https://doi.org/ 
10.17605/OSF.IO/AUJ3532.
Figure S1. Titration of antigen-concentration for bead cou-
pling, across five serum sample dilutions and two positive 
controls for PfMSP1.19, PfAMA1, and PfGLURP.R2. 
Filled circles represent the EC50 specific to the serum dilu-
tion and positive control. Vertical black line is the median EC50 
concentration across all serum dilutions and positive controls.
Figure S2. Titration of antigen-concentration for bead cou-
pling, across five serum sample dilutions and two positive 
controls for Etramp5.Ag1 and Etramp4.Ag2. Filled circles 
represent the EC50 specific to the serum dilution and positive 
control. Vertical black line is the median EC50 concentration 
across all serum dilutions and positive controls.
Figure S3. Titration of antigen-concentration for bead cou-
pling, across five serum sample dilutions and two positive 
controls for GEXP18 and HSP40.Ag1. Filled circles repre-
sent the EC50 specific to the serum dilution and positive control. 
Vertical black line is the median EC50 concentration across all 
serum dilutions and positive controls.
Figure S4. Median fluorescence intensity (MFI) for PfMSP119 
and PfGLURP.R2 of positive and negative samples for 
each buffer composition. Buffer compositions tested include 
buffer A (red), buffer A with E. coli lysate (pink), buffer B 
(blue), and buffer B with E. coli lysate (light blue). MFI for 
positive samples shown in colour (left) and corresponding 
negatives samples in grey (right) for each buffer composition.
Figure S5. Median fluorescence intensity (MFI) for Etramp5.
Ag1 and Etramp4.Ag2 of positive and negative samples 
for each buffer composition. Buffer compositions tested include 
buffer A (red), buffer A with E. coli lysate (pink), buffer B 
(blue), and buffer B with E. coli lysate (light blue). MFI for 
positive samples shown in colour (left) and corresponding 
negatives samples in grey (right) for each buffer composition.
Figure S6. Median fluorescence intensity (MFI) for HSP40.
Ag1 and Hyp2 of positive and negative samples for each 
buffer composition. Buffer compositions tested include buffer 
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A (red), buffer A with E. coli lysate (pink), buffer B (blue), 
and buffer B with E. coli lysate (light blue). MFI for positive 
samples shown in colour (left) and corresponding negatives 
samples in grey (right) for each buffer composition.
Figure S7. Serum sample dilution optimisation. Mean 
median fluorescence intensity (MFI) of positive and negative 
samples tested at four serum sample dilutions (1:100, pink; 1:500, 
blue; 1:1000, green; 1:2000, purple). Median MFI of negative 
samples are shown in grey to the right of positive samples 
shown in colour.
Figure S8. Levey-Jennings plots for Luminex plate qual-
ity control. Solid points represent the median fluorescence 
intensity (MFI) values of positive controls, ordered left to 
right by date of plate processing. Solid horizontal lines repre-
sent mean positive control MFI of the reference plates and the 
dotted lines represent MFI values of either one or two stand-
ard deviations from the mean. Coloured lines are the linear 
regression fit (mean and 95%CI) of change in MFI by date of 
plate processing, representing estimated signal degradation over 
a period of 2 months.
Figure S9. Loess normalisation PfMSP119 and PfGLURP.R2. 
Loess normalisation of antigens PfMSP119 and PfGLURP.R2 
is illustrated for one example plate based on cross-sectional 
samples from The Gambia. Upper two panels show the loess 
fit (red) and linear fit (blue) of ∆ MFI on the y-axis (the 
difference in unadjusted MFI of the standard curve of a single 
plate and the mean MFI of all standard curves from ten reference 
plates) and mean MFI on the x-axis. Lower two panels show 
the raw MFI values of individual samples on the x-axis versus 
normalised MFI values on the y-axis, and the equality line is 
shown diagonally in red. 
Figure S10. Loess normalisation Etramp5.Ag1 and Etramp4.
Ag2. Loess normalisation of antigens Etramp5.Ag1 and 
Etramp4.Ag2 is illustrated for one example plate based on cross-
sectional samples from The Gambia. Upper two panels show 
the loess fit (red) and linear fit (blue) of ∆ MFI on the y-axis 
(the difference in unadjusted MFI of the standard curve of a sin-
gle plate and the mean MFI of all standard curves from ten 
reference plates) and mean MFI on the x-axis. Lower two pan-
els show the raw MFI values of individual samples on the x-axis 
versus normalised MFI values on the y-axis, and the equality 
line is shown diagonally in red.
Figure S11. Loess normalisation HSP40.Ag1 and Hyp2. 
Loess normalisation of antigens HSP40.Ag1 and Hyp2 is 
illustrated for one example plate based on cross-sectional sam-
ples from The Gambia. Upper two panels show the loess fit (red) 
and linear fit (blue) of ∆ MFI on the y-axis (the difference in 
unadjusted MFI of the standard curve of a single plate and the 
mean MFI of all standard curves from ten reference plates) and 
mean MFI on the x-axis. Lower two panels show the raw MFI 
values of individual samples on the x-axis versus normalised 
MFI values on the y-axis, and the equality line is shown 
diagonally in red.
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Antibody responses have been used to characterize transmission and exposure history in
malaria-endemic settings for over a decade. The authors are one of the leading groups on such studies,
especially   seroepidemiology. In this study, they carefully validated their Luminex-basedP. falciparum
antibody measurement system using eight   recombinant antigens, associated with long- andP. falciparum
short-lived antibody responses. They finally standardized antigen-specific bead
coupling concentrations, buffer compositions, storage conditions, limits of quantifications and
normalization strategies. The results in this work will be very useful for the current and future expansion of
the inclusion of new antigens in this Luminex-based platform. I have a few comments that need to be
considered:
1. For which field setting can the MAGPIX platform be applicable (Target Product Profile)? For example, a
local hospital with back-up electric generator or a bigger laboratory in the central city.
2. 6 out of 8 antigens used in this study were expressed as GST-fused recombinant proteins in   asE. coli
shown in Table 1. GST and TT were also included as negative controls. 1) Please clarify how to use MFI
on negative controls to normalize MFI on GST-fused antigens. 2) I have another concern about using
GST-fused recombinant proteins as antigens for serology because there are many endemic areas of both
Schistosomiasis and malaria. If the people had a history or co-infection with this worm, the interpretation
of the results will be very difficult. Do the authors have any idea how to overcome this challenge?
Therefore, I strongly recommend the authors to use another purification tag such as His-tag in the future
development.
Is the rationale for developing the new method (or application) clearly explained?
Yes
Is the description of the method technically sound?
Yes
Are sufficient details provided to allow replication of the method development and its use by
others?
Partly
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
Yes
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Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Yes
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: Malaria protein research, Malaria vaccine research, Malaria molecular biology
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however I have significant
reservations, as outlined above.
Author Response 07 Apr 2020
, London School of Hygiene & Tropical Medicine, London, UKKevin Tetteh
Reviewer 2
We would like to thank Dr Tsuboi for his useful comments
For which field setting can the MAGPIX platform be applicable (Target Product Profile)?
For example, a local hospital with back-up electric generator or a bigger laboratory in the
central city.
Together with our international colleagues we have demonstrated the utility of the MagPix platform
in a number of different settings as evidenced in the following publications (Surendra H et al. BMC
Med. 2020 Jan 28;18(1):9. doi: 10.1186/s12916-019-1482-7. [PMID: 31987052]; van den Hoogen
Sci Rep. 2020 Jan 24;10(1):1135. doi: 10.1038/s41598-020-57876-0. [PMID: 31980693]; Achan J
et al. Clin Infect Dis. 2019 Aug 12. pii: ciz740. doi: 10.1093/cid/ciz740. [PMID: 31980693]). We and
others have shown that the platform can be used in a wide range of study sites as long as there is
access to an uninterrupted power supply. Apart from the Magpix reader, magnetic plate and
coupled microspheres, no additional specialist equipment is required, outside of typical laboratory
materials. 
“Minimal specialist equipment is required aside from a Luminex reader, a magnetic plate, and
coupled microspheres and standard ELISA laboratory reagents. Therefore, Luminex-based
processing is feasible in a range of endemics settings, from local hospitals with back-up electric
generators (with consistent supply for at least two 90 minutes incubations and a one hour plate
reading) to larger laboratories in urban settings.”
6 out of 8 antigens used in this study were expressed as GST-fused recombinant proteins
in  as shown in Table 1. GST and TT were also included as negative controls. 1)E. coli
Please clarify how to use MFI on negative controls to normalize MFI on GST-fused
antigens. 2) I have another concern about using GST-fused recombinant proteins as
antigens for serology because there are many endemic areas of both Schistosomiasis and
malaria. If the people had a history or co-infection with this worm, the interpretation of the
results will be very difficult. Do the authors have any idea how to overcome this
challenge? Therefore, I strongly recommend the authors to use another purification tag
such as His-tag in the future development.
Tetanus toxoid (TT) and GST are not intended as ‘negative controls’. TT was included as an
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 1.  
2.  
3.  
such as His-tag in the future development.
Tetanus toxoid (TT) and GST are not intended as ‘negative controls’. TT was included as an
internal positive control as it is expected that most samples, including malaria endemic and
naïve controls, will have measurable MFI values against the TT coupled beads and
therefore confirm that the assay was run successfully. GST only responses are measured
and subtracted from target responses to account for any possible non-specific GST
reactivity in samples.
We understand the reviewer’s concern. The GST-tag is based on a glutathione
s-transferase from Schistosoma mansoni, which is prevalent in some of the malaria
endemic sites under test. However, we and others have found that subtracting the
non-specific, or potentially cross-reactive responses to the fusion tag has been
demonstrated elsewhere to be effect in measuring antigen specific responses (Dobaño C et
al J Infect Dis 2008 [PMID: 18260767]; Ahlborg N et al Clin Exp Immunol 2002 [PMID:
12165089]). That said, we are currently exploring other expression platforms including
his-tag to eliminate this concern in the future.
 No competing interests were disclosed.Competing Interests:
 20 February 2019Reviewer Report
https://doi.org/10.21956/wellcomeopenres.16307.r34827
© 2019 Rogier E. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution License
work is properly cited.
   Eric Rogier
Malaria Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA
The authors describe comparisons of immunoassay conditions utilizing a bead-based system as applied
to a  8-antigen panel. Data is provided for how antigen coupling concentrationsPlasmodium falciparum 
are selected, differences in sample dilution and blocking buffers, and coupled bead storage conditions.
Additionally, the authors outline a normalization scheme when multiple assay plates are run for a study.
The report is timely, as multiple malaria groups are now using bead-based multiplex assays and
investigating new antigens to augment panels. The authors could provide some additional information
regarding the details of their assay and reporting, as well as make some text in the manuscript clearer for
the inexperienced reader. Furthermore, some figures currently show data for all 8 Pf antigens, whereas
others only display data for 2 or 3. At the least, the data for all 8 antigens should be included as
Supplementary data.
  
Minor suggestions:
Are references available for more detailed information of recombinant antigen production for the 8
presented here (or similar)?
 
Explain in Methods how the beads were washed.
 
Provide detail about GST and tetanus toxoid couplings. Explain what is meant by: “to allow for
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 3.  
4.  
5.  
6.  
7.  
8.  
9.  
Provide detail about GST and tetanus toxoid couplings. Explain what is meant by: “to allow for
correction of any GST-specific immunoglobulin”.
 
Explain how “clarified   lysate” was produced.E. coli
 
Are MFI values reported or MFI-background values?
 
The current flowchart in Figure 1 is a little difficult to read, especially for someone unfamiliar with
this assay. It is suggested to add some more text to the boxes to clarify and read more like a
protocol. For example, one box reads: “8 uL coupled microspheres, 5 mL buffer A, (1,000 beads
per well)”, and would be clearer with: “8 uL of coupled beads added to 5 mL buffer A (for a
concentration of approximately 1,000 beads per well)”.
 
Titration curves in Figure 2 for the other antigens would be helpful in Supplementary.
 
Unfortunately, in Figure 3, the authors do not include a storage condition of 4 degrees which most
researchers will choose to keep their coupled beads at for practical storage. It’s not clear why
conditions starting at room temperature and increasing were chosen, as this wouldn’t be utilized by
a group having MAGPIX technology. Even an interruption of cold-chain would only be for a short
period of time for this type of work.  
 
For the Buffer Composition comparisons, the authors only offer data for two Pf antigens in Figure 4
and Supplementary Table 4. Please provide this same comparison for all 8 Pf antigens as well as
the two control proteins. The same for Figure 6 in that all antigens should at least be shown in
Supplementary.  
Is the rationale for developing the new method (or application) clearly explained?
Yes
Is the description of the method technically sound?
Yes
Are sufficient details provided to allow replication of the method development and its use by
others?
Partly
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
Yes
Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Yes
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: Malaria serological assays
I confirm that I have read this submission and believe that I have an appropriate level of
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 I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however I have significant
reservations, as outlined above.
Author Response 07 Apr 2020
, London School of Hygiene & Tropical Medicine, London, UKKevin Tetteh
Reviewer 1
We would like to thank the reviewer for their useful comments:
Are references available for more detailed information of recombinant antigen production
for the 8 presented here (or similar)? 
With the exception of AMA1, the remaining antigens described in the manuscript were generated
following methods described in the manuscript and elsewhere (Herman et al. PLoS Negl Trop Dis.
2018 Jun 14;12(6):e0006457. doi: 10.1371/journal.pntd.0006457. [PMID: 29902183]; Tetteh KK et
al. Infect Immun. 2013 Oct;81(10):3835-42. doi: 10.1128/IAI.00301-13. [PMID: 23897617]; Polley
SD et al. Infect Immun. 2003 Apr;71(4):1833-42. [PMID: 12654798]). The text has been adjusted to
reflect this:
 
“Each antigen was generated and expressed in Escherichia coli as glutathione S-transferase
(GST)-tagged fusion proteins using methods as described elsewhere (PMID: 29902183, PMID:
23897617, PMID: 12654798). The exception to the panel was PfAMA1, which was expressed in
Pichia pastoris as a histidine-tagged protein (PMID: 17192270).”
 
Explain in Methods how the beads were washed.
 
The following sentences have been included into the qSAT procedure to clarify the wash step. 
 
“Next, 50 μl of this combined microsphere mixture was added to a 96-well flat bottom plate
(BioPlex Pro™, Bio-Rad Laboratories, UK) and washed once by placing the assay plate onto a
magnetic plate separator (Bio-Plex®, Bio-Rad Laboratories, UK) and incubated for 2 minutes at
room temperature. Plates were then inverted forcefully to remove the liquid and 100 μl of PBS-T
(1xPBS, 0.05% Tween-20) added to each well. “
 
Provide detail about GST and tetanus toxoid couplings. Explain what is meant by: “to
allow for correction of any GST-specific immunoglobulin”.
 
Tetanus toxoid (TT) coupled beads were included as the Tetanus vaccine is widely used and
therefore useful as an internal control. It would be expected that most samples, including malaria
endemic and naïve controls will have measurable MFI values against the TT coupled beads and
therefore confirm that the assay was run successfully. This is a particularly useful control when
samples are assayed as single wells (with no duplicate result to compare to).
The GST-tag used in the purification of the recombinant proteins is based on a glutathione
s-transferase from Schistosoma mansoni, a blood trematode common to some of the malaria
endemic sites under test. As several of the antigens are expressed as GST-tagged fusion proteins
it is important to correct for any background, or non-malaria specific reactivity to the GST-tag.
Assaying for reactivity to beads coupled with purified GST allows us to measure the level of
reactivity to the tag, if any, and background correct the response by subtracting the GST response.
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 Assaying for reactivity to beads coupled with purified GST allows us to measure the level of
reactivity to the tag, if any, and background correct the response by subtracting the GST response.
Subtraction of non-specific, or potentially cross-reactive responses to fusion tags in serological
studies has been demonstrated elsewhere (Dobaño C et al J Infect Dis 2008 [PMID: 18260767];
Ahlborg N et al Clin Exp Immunol 2002 [PMID: 12165089])
 
Explain how “clarified  lysate” was produced.E. coli
To produce the bacterial lysate, untransformed E.coli were cultured using the Studier recipe for
autoinduction media under the same conditions as used for expression of the recombinant protein
with one exception. The addition of an antibiotic for selection of recombinants is omitted. After
culturing for approximately 18 hours at 37 C, the cells are harvested by centrifugation,
resuspended in PBS and lysed using a high pressure homogeniser. The lysed material is then
centrifuged at 16,000 rpm for 15 min to pellet the lysed E.coli membranes. The clarified lysate is
then aliquoted and stored at -20 C until needed. 
As sentence has been included in the text to summarise this point:
“Bacterial lysate was generated from the culture of untransformed E.coli and used in the
preparation of assay buffers as non-specific protein to eliminate background reactivity to E.coli
proteins (PMID: 26216993).”
 
Are MFI values reported or MFI-background values?
 
All results are reported as MFI-background and the following sentence has been added to the
methods: “All data reported and analysed are in units of background subtracted MFI.”
 
 
The current flowchart in Figure 1 is a little difficult to read, especially for someone
unfamiliar with this assay. It is suggested to add some more text to the boxes to clarify
and read more like a protocol. For example, one box reads: “8 uL coupled microspheres, 5
mL buffer A, (1,000 beads per well)”, and would be clearer with: “8 uL of coupled beads
added to 5 mL buffer A (for a concentration of approximately 1,000 beads per well)”.
 
We appreciate the reviewer’s comments and the flowchart has been edited accordingly and a new
version uploaded.
 
Titration curves in Figure 2 for the other antigens would be helpful in Supplementary.
 
The titrations curves for the remaining antigens were previously included in the supplement
(Figures S1,S2, and S3)
 
Unfortunately, in Figure 3, the authors do not include a storage condition of 4 degrees
which most researchers will choose to keep their coupled beads at for practical storage.
It’s not clear why conditions starting at room temperature and increasing were chosen, as
this wouldn’t be utilized by a group having MAGPIX technology. Even an interruption of
cold-chain would only be for a short period of time for this type of work
 
Coupled and uncoupled beads are stored at 4 C as standard. However, coupled beads are
routinely shipped globally to collaborator sites, where disruptions to the cold chain can and has
occurred. As such we felt it was necessary to evaluate the potential impact of suboptimal shipping
and/or storage conditions on the functionality of the coupled beads. The following text has been
included in the discussion as a point to consider in future studies: “Temperatures of 22°C and
0
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 included in the discussion as a point to consider in future studies: “Temperatures of 22°C and
above were tested in this study to assess the potential impact of disrupted cold chain during
shipping to or long-term storage in laboratories in low- and middle-income settings. Further work
should also investigate bead stability during long-term storage at 4°C, the standard storage
condition for most research groups using Luminex platforms.”
 
 
For the Buffer Composition comparisons, the authors only offer data for two Pf antigens in
Figure 4 and Supplementary Table 4. Please provide this same comparison for all 8 Pf
antigens as well as the two control proteins. The same for Figure 6 in that all antigens
should at least be shown in Supplementary.
This has now been included in Supplementary data as Figures S4-6 for buffer testing, and Figures
 S9-11 for loess normalisation
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